Fulgent Genetics, Inc. (FLGT)

NASDAQ: FLGT · Real-Time Price · USD
20.31
-0.10 (-0.47%)
Aug 8, 2025, 11:41 AM - Market open
-0.47%
Market Cap621.67M
Revenue (ttm)303.22M
Net Income (ttm)-51.02M
Shares Out 30.61M
EPS (ttm)-1.67
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume68,368
Open20.55
Previous Close20.41
Day's Range20.16 - 20.56
52-Week Range14.57 - 25.00
Beta0.83
AnalystsBuy
Price Target25.33 (+24.72%)
Earnings DateAug 1, 2025

About PARA

Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive he... [Read more]

Sector Healthcare
IPO Date Sep 29, 2016
Employees 1,313
Stock Exchange NASDAQ
Ticker Symbol FLGT
Full Company Profile

Financial Performance

In 2024, Fulgent Genetics's revenue was $283.47 million, a decrease of -1.99% compared to the previous year's $289.21 million. Losses were -$42.71 million, -74.55% less than in 2023.

Financial Statements

Analyst Summary

According to 3 analysts, the average rating for FLGT stock is "Buy." The 12-month stock price target is $25.33, which is an increase of 24.72% from the latest price.

Price Target
$25.33
(24.72% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Fulgent Genetics, Inc. (FLGT) Q2 2025 Earnings Call Transcript

Fulgent Genetics, Inc. (NASDAQ:FLGT) Q2 2025 Earnings Conference Call August 1, 2025 8:30 AM ET Company Participants Brandon Perthuis - Chief Commercial Officer Ming Hsieh - Chairman & CEO Paul Kim -...

6 days ago - Seeking Alpha

Fulgent Reports Second Quarter 2025 Financial Results

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeuti...

7 days ago - Business Wire

Fulgent Genetics Receives EU CE Mark for FulgentExome & FulgentPLM

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeuti...

22 days ago - Business Wire

Fulgent to Announce Second Quarter 2025 Financial Results on Friday, August 1, 2025

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic...

4 weeks ago - Business Wire

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Fulgent Genetics, Inc. (FLGT) And Encourages Shareholders to Reach Out

NEW YORK, NY / ACCESS Newswire / June 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulgent Genetics, Inc. ("Fulgent" or "the Company") (NA...

2 months ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Fulgent Genetics, Inc. (FLGT) and Encourages Shareholders to Learn More About the Investigation

NEW YORK, NY / ACCESS Newswire / June 9, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulgent Genetics, Inc. ("Fulgent" or "the Company") (NAS...

2 months ago - Accesswire

Fulgent Genetics, Inc. (FLGT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

NEW YORK, NY / ACCESS Newswire / June 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulgent Genetics, Inc. ("Fulgent" or "the Company") (NAS...

2 months ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Encourages Fulgent Genetics, Inc. (FLGT) Shareholders to Inquire about Securities Investigation

NEW YORK, NY / ACCESS Newswire / June 6, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulgent Genetics, Inc. ("Fulgent" or "the Company") (NAS...

2 months ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Is Investigating Fulgent Genetics, Inc. (FLGT) And Encourages Investors to Connect

NEW YORK, NY / ACCESS Newswire / June 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulgent Genetics, Inc. ("Fulgent" or "the Company") (NAS...

2 months ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Encourages Fulgent Genetics, Inc. (FLGT) Stockholders to Inquire about Securities Investigation

NEW YORK, NY / ACCESS Newswire / June 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulgent Genetics, Inc. ("Fulgent" or "the Company") (NAS...

2 months ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Fulgent Genetics, Inc. (FLGT) and Encourages Investors to Learn More About the Investigation

NEW YORK, NY / ACCESS Newswire / June 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulgent Genetics, Inc. ("Fulgent" or "the Company") (NAS...

2 months ago - Accesswire

Fulgent Genetics, Inc. (FLGT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

NEW YORK, NY / ACCESS Newswire / June 2, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulgent Genetics, Inc. ("Fulgent" or "the Company") (NAS...

2 months ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Is Investigating Fulgent Genetics, Inc. (FLGT) And Encourages Stockholders to Connect

NEW YORK, NY / ACCESS Newswire / May 30, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulgent Genetics, Inc. ("Fulgent" or "the Company") (NAS...

2 months ago - Accesswire

Fulgent Genetics, Inc. (FLGT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

NEW YORK, NY / ACCESS Newswire / May 29, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulgent Genetics, Inc. ("Fulgent" or "the Company") (NAS...

2 months ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Fulgent Genetics, Inc. (FLGT) and Encourages Stockholders to Learn More About the Investigation

NEW YORK, NY / ACCESS Newswire / May 28, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulgent Genetics, Inc. ("Fulgent" or "the Company") (NAS...

2 months ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Encourages Fulgent Genetics, Inc. (FLGT) Investors to Inquire about Securities Investigation

NEW YORK, NY / ACCESS Newswire / May 27, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulgent Genetics, Inc. ("Fulgent" or "the Company") (NAS...

2 months ago - Accesswire

FLGT Investors Have Opportunity to Join Fulgent Genetics, Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES--(BUSINESS WIRE)--FLGT Investors Have Opportunity to Join Fulgent Genetics, Inc. Fraud Investigation with the Schall Law Firm.

2 months ago - Business Wire

Wolf Haldenstein Adler Freeman & Herz LLP is investigating Fulgent Genetics, Inc

PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION  NEW YORK , May 19, 2025 /PRNewswire/ --  Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights...

2 months ago - PRNewsWire

Fulgent Genetics, Inc. (FLGT) Q1 2025 Earnings Call Transcript

Fulgent Genetics, Inc. (FLGT) Q1 2025 Earnings Call Transcript

3 months ago - Seeking Alpha

Fulgent Reports First Quarter 2025 Financial Results

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeuti...

3 months ago - Business Wire

Fulgent to Announce First Quarter 2025 Financial Results on Friday, May 2, 2025

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic...

4 months ago - Business Wire

Stock Picks From Seeking Alpha's March 2025 New Analysts

In March, we welcomed 30 new analysts to Seeking Alpha, and in this article we are showcasing their stock picks and investment strategies. Our analysts covered a diverse set of industries—including IT...

Other symbols: AIARGXCCLCEPUCFCROXCUK
4 months ago - Seeking Alpha

Fulgent Genetics: Undervalued, CFO Buying, And Promising Drug Candidates Make It A Buy

CFO bought 1.5 million worth on March 5th, a Price/Book ratio of 0.43x and a Net Current Assets Value (NCAV) of 0.68x that day. Now it's trading at 0.47x Price/Book Value and 0.72x NCAV, showing a sig...

5 months ago - Seeking Alpha

Fulgent Genetics, Inc. (FLGT) Q4 2024 Earnings Conference Call Transcript

Fulgent Genetics, Inc. (NASDAQ:FLGT) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Melanie Solomon - IR Ming Hsieh - Chairman and CEO Brandon Perthuis - Chief Com...

5 months ago - Seeking Alpha

Fulgent Reports Fourth Quarter and Full Year 2024 Financial Results

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeuti...

5 months ago - Business Wire